A new study published in JSCAI has revealed a lower risk of cardiovascular events for patients with Type 1 diabetes (often ...

However, an antibody called teplizumab ... from the USA with around 730,000 euros over three years. Type 1 diabetes causes secondary diseases According to estimates by the German Diabetes Society ...

They were considered eligible if they were a sibling or offspring of a patient with type 1 diabetes, were positive for at least two islet autoantibodies (insulin autoantibody [IAA], GAD ...

The cause of type 1 diabetes remains unknown and is a central focus of Boston College Assistant Professor of Biology Emrah Altindis and others in his field hoping to find new ways to help 1.6 million ...

A new study published in the Journal of the Society for Cardiovascular Angiography & Interventions has revealed a lower risk ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

therapy for a 20-year old Emirati patient with type 1 diabetes in the UAE. This groundbreaking treatment resulted in a significant improvement in blood sugar levels and diabetes antibodies, with ...

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd ... aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity.

ImmunoPrecise Antibodies Ltd. (IPA ... therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's ...